GALECTIN THERAPEUTICS INC — Director's Dealing 2013

Oct 9, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2013-10-07

Reporting Person: CZIRR JAMES C (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-10-07	Common Stock	S	100000	$11.7916	Disposed	8969422	Indirect
2013-10-08	Common Stock	S	12000	$12.3558	Disposed	8957422	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	843450	Direct
Common Stock	179232	Indirect

Footnotes

F1: Reflects weighted average price. Range of prices were between $11.5335 and $12.136. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F2: Reflects weighted average price. Range of prices were between $12.00 and $12.51. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F3: Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.